TPExtreme: Randomized, Controlled Trial of Platinum-Cetuximab Combined Either With Docetaxel (TPEx) or With 5FU (Extreme) in Patients With Recurrent/Metastatic Squamous Cell Cancer of the Head and Neck
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin; Docetaxel; Fluorouracil; Granulocyte colony-stimulating factors
- Indications Head and neck cancer
- Focus Therapeutic Use
- Acronyms TPExtreme
- 15 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 15 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 15 Feb 2018 Status changed from recruiting to active, no longer recruiting.